We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




TESARO and Myriad Expand Collaboration with New CDx Pair

By LabMedica International staff writers
Posted on 01 Dec 2014
Print article
The new collaboration will utilize the Myriad Genetics (Salt Lake City, UT, USA, and Zurich, Switzerland) companion diagnostic (CDx) “myChoice HRD” test to identify tumors with a homologous recombination deficiency (HRD). Under the terms of the agreement, TESARO, Inc. (Waltham, MA, USA) will use the test to enrich the target population for potential responders to niraparib. Myriad will provide testing services and pursue necessary regulatory approvals in support of TESARO's development of niraparib (a potent poly-(ADP-ribose)-polymerase inhibitor).

"We are excited to be expanding our collaboration with TESARO," said Jerry Lanchbury, PhD, chief scientific officer at Myriad, "myChoice HRD utilizes three proprietary measures to assess the genomic scar associated with the loss of DNA repair and has been shown in multiple clinical studies to be the most comprehensive predictor of tumor response to DNA-damaging agents such as niraparib."

Many cancer patients may be candidates for treatment with DNA-damaging agents. Myriad's proprietary myChoice HRD detects DNA scars indicative of a tumor that has lost the ability to repair double-stranded DNA breaks—resulting in increased susceptibility to DNA-damaging drugs. High HRD scores reflective of DNA-repair deficiencies are prevalent in all known breast cancer subtypes and most other major cancers. In previously published data, Myriad showed that the myChoice HRD test predicted drug-response to platinum therapy in triple-negative breast cancer patients.

"Myriad's myChoice HRD diagnostic test identifies inherent biology of the tumor and differentiates tumors with homologous repair deficiencies from those without such deficiencies," said Mary Lynne Hedley, PhD, president and COO of TESARO, "Niraparib sensitivity in patient-derived xenograft models is associated with HRD status as defined by the myChoice HRD test." New data, demonstrating that the myChoice HRD test score is predictive of niraparib sensitivity in patient-derived xenograft models of ovarian cancer, have now presented by Mayo Clinic Prof. Paul Haluska, Jr, MD, PhD, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Barcelona, Spain).

In the xenograft study, patient-derived xenografts were created from more than 100 high-grade serious ovarian cancer tumor samples. HRD testing was performed on each sample using myChoice HRD to define HRD status, detect BRCA-1 and -2 mutations, and identify hypermethylation of BRCA genes. Approximately half of these models were HRD positive and are being evaluated for sensitivity to niraparib in vivo. Preliminary data from treated models indicate all models that responded to niraparib treatment had an HRD score above the predetermined cutoff value and included both BRCA mutant and BRCA wild type tumors. Evaluation of niraparib sensitivity across the full set of selected models is ongoing. These initial results indicate that identifying patients with homologous recombination deficiencies using myChoice HRD may help to identify patients who are most likely to respond to treatment with niraparib.

Related Links:

TESARO
Myriad Genetics, Inc.
Myriad Genetics, GmbH


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.